Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose and effect of pimasertib in combination with
bintrafusp alfa in treating patients with cancer that has spread to the brain (brain
metastases). Immunotherapy with bintrafusp alfa, a bifunctional fusion protein composed of
the monoclonal antibody anti-PD-L1 and TGF-beta, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Pimasertib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving pimasertib and bintrafusp alfa may help to prevent or delay the cancer from
progressing (getting worse) and/or coming back.